Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study
This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.
Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Tianjin、中国、300060
- Tianjin Medical University Cancer Institute and Hospital
-
コンタクト:
- Ting Deng
- 電話番号:+86 8008180388
- メール:xymcdengting@126.com
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- Affiliated Drum Tower Hospital, Medical School of Nanjing University
-
コンタクト:
- Jia Wei
- 電話番号:+86 25 8310 6666
- メール:jiawei99@nju.edu.cn
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital, Sichuan University
-
コンタクト:
- Hongfeng Gou
- 電話番号:+86-28-85422114
- メール:joan_gou1977@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 18-75 years.
- Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy.
- HER2-negative status.
- At least one measurable or evaluable lesion per RECIST v1.1.
- PD-L1 CPS <5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory.
- ECOG PS 0-1
- Life expectancy ≥3 months.
Exclusion Criteria:
- Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment.
- Active tumor bleeding.
- Severe gastrointestinal obstruction or difficulty swallowing tablets.
- Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions.
- Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity.
- Grade ≥3 hypersensitivity to monoclonal antibodies or chemotherapy components.
- History of seizures, CNS metastases, spinal cord compression, or meningeal metastases.
- Clinically significant cardiovascular or cerebrovascular disease.
- History of severe toxicity requiring permanent discontinuation of immune checkpoint inhibitors or study-related treatment.
- History of noninfectious enteritis requiring corticosteroids within 1 year before treatment.
- Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension.
- Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental Arm
Sintilimab Plus Ipilimumab N01 and Chemotherapy |
Patients in the experimental arm will receive a single dose of ipilimumab N01 (3 mg/kg IV), combined with sintilimab (200 mg IV, Q3W) and XELOX or SOX chemotherapy for 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. Subsequent dosing of ipilimumab N01 will be determined based on radiological assessments per RECIST v1.1 and safety evaluations. |
|
アクティブコンパレータ:Active Comparator
Sintilimab Plus Chemotherapy |
Patients in the active comparator arm will receive sintilimab (200 mg IV, Q3W) plus XELOX or SOX chemotherapy for up to 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:From randomization to death from any cause, assessed up to 48 months.
|
Defined as the time from randomization to death from any cause |
From randomization to death from any cause, assessed up to 48 months.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:From baseline to disease progression, assessed up to 24 months.
|
PFS is defined as the time from randomization to the first disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
From baseline to disease progression, assessed up to 24 months.
|
|
Objective Response Rate (ORR)
時間枠:From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
ORR is defined as the percentage of response-evaluable participants with measurable disease at baseline who achieve a best overall response of confirmed complete response (CR) or partial response (PR) per RECIST v1.1. |
From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
|
Incidence of Adverse Events (AEs)
時間枠:From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
Percentage of participants experiencing AEs, including severity and relationship to study treatment. |
From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2026-1221-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。